SILO - Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy | Benzinga
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly advancing through analytical testing and preclinical trials toward determining drug release and stability following approval by state and federal authorities.
The psychedelics biotech has partnered with Sever Pharma Solutions for development and manufacturing. The implant’s design, including dosage and time-release delivery, aims to become an at-home pain relief treatment.
"Many chronic pain sufferers are seeking a non-opioid treatment that offers relief. Based on findings to date, ...